Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABRA1 | P14867 | 4/20 | 0.39 |
| ▸ | GABRB2 | P47870 | 4/20 | 0.39 |
| ▸ | NSD2 | O96028 | 1/20 | 0.34 |
| ▸ | HK1 | P19367 | 1/20 | 0.34 |
| ▸ | HKDC1 | Q2TB90 | 1/20 | 0.34 |
| ▸ | POLB | P06746 | 2/20 | 0.32 |
| ▸ | GAA | P10253 | 1/20 | 0.32 |
| ▸ | CRHR1 | P34998 | 1/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | SLC18A3 | Q16572 | 2/20 | 0.31 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.31 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.31 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.31 |
| ▸ | BCHE | P06276 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6492063 | 0.88 | GABRA1 (0.39) | GABRA1GABRB2POLBGAACRHR1 | |
| SCHEMBL6492513 | 0.80 | NSD2 (0.32) | NSD2HK1HKDC1 | |
| SCHEMBL6488001 | 0.78 | GABRA1 (0.39) | GABRA1GABRB2NSD2HK1HKDC1 | |
| SCHEMBL6480327 | 0.76 | FABP7 (0.35) | GABRA1GABRB2POLBMTNR1AMTNR1B | |
| SCHEMBL6480617 | 0.74 | GABRA1 (0.32) | GABRA1GABRB2POLBMTNR1AMTNR1B | |
| SCHEMBL6489783 | 0.73 | NSD2 (0.30) | NSD2HK1HKDC1 | |
| SCHEMBL26148676 | 0.68 | GABRA1 (0.47) | GABRA1GABRB2POLBGAAKDM4E | |
| SCHEMBL6492062 | 0.68 | GABRA1 (0.39) | GABRA1GABRB2POLBGAACRHR1 | |
| SCHEMBL30829053 | 0.67 | MTNR1A (0.51) | GABRA1GABRB2POLBGAAKDM4E | |
| SCHEMBL26148675 | 0.66 | GABRA1 (0.45) | GABRA1GABRB2POLBGAACRHR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050288238-A1 | Benzocyclodecane derivatives with antitumor activity | PFIZER INC | 2005-12-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050288238-A1 | Benzocyclodecane derivatives with antitumor activity | H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, OR10J3, BCL6 | GABRA1 1090/4885GABRB2 1427/4885NSD2 2322/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.